Newborn (NB) 4 screening for galactosemia is done primarily to detect clinically devastating galactosemia due to defective function of galactose-1-phosphate uridyltransferase (GALT) (1 ) . Increases in blood galactose (Gal) are also observed in other conditions, however: in the relatively rare galactokinase (GALK) deficiency, which can have serious sequelae; in partial GALT deficiency, which has no clinical consequences; and in UDP-galactose-4-epimerase (GALE) deficiency, which has 1 common benign form and 1 extremely rare untreatable form with severe clinical outcomes (2, 3 ) . Additionally, there are other transient galactosemias of unknown cause and other known benign variants that are routinely flagged in NB screening. Recently, Sakura et al. reported that congenital portal-systemic shunt, rather than hereditary galactosemias, is the most common cause of persistent hypergalactosemia in NB screening in Hiroshima, Japan (4 ) . The Duarte/classic compound heterozygote variant (D/G galactosemia) is often the cause of hypergalactosemia and is frequently flagged as positive in NB-screening programs. The urgent reporting of an increased Gal concentration, with or without GALT deficiency, sets off a chain of events: immediate notification of the Department of Health, primary care physicians, and/or metabolic specialists; bringing the NB in for observation; confirmatory testing; and possible diet change. These events are often nonproductive, wasteful of medical resources, and traumatic for families.
To assess the specificity of galactosemia screening, we compiled NB-screening data in our laboratory from January 1, 2001 , to March 1, 2006 , for Ͼ1.3 ϫ 10 6 NBs.
These data included Gal and GALT measurements for all screened NBs. Samples with an increased Gal concentration and/or low GALT activity were also assayed for galactose 1-phosphate (Gal-1-P) and subjected to qualitative DNA testing for 4 common mutations. Whenever possible, clinical outcomes were obtained. The database summarized here for the initial phase of the study was provided as a starting point for a series of discussions in 2006 that were headed by the Pennsylvania Department of Health (PA DOH) and carried out in conjunction with the laboratory and directors of the 2 Pennsylvania galactosemia treatment centers. The goal of the discussions was to analyze these data within the clinical contexts in order to match the reporting of galactosemia with the clinical phenotype. Combining the patterns provided by mining the large amount of data with the clinical experience of the treatment centers suggested changes in the reporting and subsequent revision of some follow-up protocols. For nonclassic galactosemias, our data suggested that the new protocol would produce fewer urgent referrals, conserve time and effort, reduce financial costs, and reduce emotional stress for a substantial number of families. We implemented the recommended reporting and protocol changes in 2006 and have tracked outcomes for 2 years (2007 and 2008). We report our combined results for both phases of the study.
Materials and Methods
Whatman 903-type filter papers (previously Schleicher & Schuell 903) were used for all collections and all assays.
TOTAL Gal
Total Gal (free Gal plus Gal-1-P) was measured by first extracting a filter paper punch (3/16th in) of a blood spot from each NB. The Gal enzymatic assay uses the AstoriaPacific automated SPOTCHECK continuous-flow assay system as modified by Hoffman et al. (5 ) . Alkaline phosphatase converted the Gal-1-P in the sample to Gal in the first incubation step. The Gal conversion to galactonolactone by the NAD ϩ -NADH-coupled Gal dehydrogenase reaction was then monitored by the change in NADH fluorescence. The mean total Gal concentration for a representative Pennsylvania NB population is 0.200 mmol/L (3.6 mg/dL) [nonparametric range of 2 SDs, 0.128 -0.483 mmol/L (2.3-8.7 mg/dL)].
MODIFIED Gal
Modified Gal was measured in samples with an increased total Gal concentration by repunching the blood spot and reanalysis with the Astoria-Pacific SPOTCHECK system, but without the alkaline phosphatase incubation of the first sample. Subsequent incubation with Gal dehydrogenase yielded NADH fluorescence due to the free Gal in the sample. The Gal-1-P concentration was measured by subtracting the total Gal concentration from the modified Gal concentration. Percentage Gal-1-P was calculated as the Gal-1-P concentration divided by total Gal concentration. The expected Gal-1-P percentage is Ͼ25% of the total Gal concentration. If the total Gal concentration is increased, a Gal-1-P value Ͼ25% suggests possible GALE deficiency, whereas a Gal-1-P value Ͻ25% suggests possible GALK deficiency.
GALT ANALYSIS
GALT activity was measured by first extracting a filter paper punch (3/16th in) of a blood spot from each NB. The assay used was the Astoria-Pacific SPOTCHECK continuous-flow assay system as modified by Sturgeon et al. (6 ) . The conversion of UDP-glucose in a series of enzymatic steps to 6-phosphogluconate was coupled to NADP ϩ -NADPH reduction with fluorescence detection. A linear calibration curve was constructed from known NADPH concentrations (in micromoles per liter). Results were expressed in micromoles per liter of fluorescence measured as a direct indication of enzymatic activity. For in-house QC samples, we obtained CVs of 17% for the low-concentration pool (mean, 40 mol/L) and 12% for the typical-concentration pool (mean, 277 mol/L). The reference interval for GALT in the NB population is approximately 150 -500 mol/L. A GALT value Յ32 mol/L is typical in GALT-deficient galactosemia, whereas GALT activity values of 41-120 mol/L are common with clinically benign mutations. We use "GALT-deficient" throughout this report to denote the laboratory observation of a low enzymatic activity, irrespective of the mutations detected.
DNA ANALYSIS
Three classic mutations in the GALT (galactose-1-phosphate uridylyltransferase) gene (Q188R, K285N, and L195P), the S135L mutation, and the Duarte variant (N314D) were detected as previously described (7 ) . DNA analysis was performed for all GALT-deficient samples (i.e., GALT Յ40 mol/L).
CRITERIA FOR REPORTING POSITIVES
Before September 2006, the PA DOH defined a positive result for non-GALT-deficient galactosemia as a Gal concentration Ն1.110 mmol/L (Ն20 mg/dL). The protocol for reporting positive results included immediate notification of the Newborn Screening Program and notification of the primary care physician with a recommendation for immediate referral of the NB to a galactosemia treatment center. Samples with a Gal concentration Ͻ1.110 mmol/L (Ͻ20 mg/dL) but Ն0.8325 mmol/L (Ն15 mg/dL) were reported as "inconclusive" on the next working day, along with a request for a repeat collection. The revised reporting protocol was implemented on September 1, 2006. In the revised protocol, only cases with a GALT value Յ40 mol/L or with a Gal value Ն1.665 mmol/L (Ն30 mg/dL) were reported as positive. Cases with a GALT value Ͼ40 mol/L and a Gal value Ն0.8325 mmol/L (Ն15 mg/ dL) but Ͻ1.665 mmol/L (Ͻ30 mg/dL) were reported as inconclusive, along with a request for repeat collection within 72 h. If the NB was on a Gal-free diet before sample collection, he/she was automatically referred to a treatment center. Otherwise, a repeat collection would be made and analyzed. If the repeat Gal value was Ն1.110 mmol/L (Ն20 mg/dL) (or GALT Յ40 mol/L), the second report stated the results as inconclusive and recommended referral of the NB to the treatment center.
COMPARATIVE AUDIT OF THE NEW REPORTING PROTOCOL
In phase 2 of this study, we 
Results
In the first phase of this study, we carried out an audit of all positive reports of galactosemias to categorize the laboratory results and then compare them with clinical outcomes. Results were presented to the Pennsylvania Newborn Screening Advisory Committee, and recommendations for changes in reporting were determined. The second phase was a 2-year study (2007, 2008) of outcomes that used the revised reporting and follow-up protocol. Fig. 1 illustrates the distribution of all of our screen-positive samples for the period January 1, 2001, to March 1, 2006 , with respect to test results. For the period surveyed, 209 samples had a Gal value Ն1.110 mmol/L (Ն20 mg/dL) and/or a GALT value Յ40 mol/L; 23 of these samples had a GALT activity Յ40 mol/L. Of the 186 screened samples with a GALT value Ͼ40 mol/L and a Gal concentration Ն1.110 mmol/L (Ն20 mg/dL), 176 had a typical Gal-1-P percentage (Ͼ25%). Twenty of these 176 cases had a total Gal concentration Ն1.665 mmol/L (Ն30 mg/dL), values consistent with possible GALE deficiency, and 10 cases had an abnormally low Gal-1-P percentage (Յ25%). Only 1 of these cases had a Gal value Ͼ1.665 mmol/L (Ͼ30 mg/dL), which is consistent with possible GALK deficiency. Table 1 summarizes the screening and DNA results for the 23 cases screened between January 1, 2001, and March 1, 2006 , that had GALT values Յ40 mol/L. In 14 cases, 2 copies of DNA mutations responsible for GALT deficiency were identified (11 homozygotes, 3 compound heterozygotes). In 4 cases, only 1 DNA mutation was identified (heterozygous G; all individuals with clinical diagnoses of GALT-deficient galactosemia). Case no. 4 was a compound heterozygote with an unidentified exon 10 variant. Case no. 10 was a confirmed case of classic disease that featured no detected mutational markers but did have an apparent partial gene deletion at a location remote from the mutation-probe sites tested. Three cases were D/G heterozygotes, and 1 sample had no detectable mutations (confirmed as classic disease by the symptoms). Table 2 summarizes the 20 cases in our initial 5-year study that had Gal concentrations Ն1.665 mmol/L (Ն30 mg/dL), GALT values Ͼ40 mol/L, and Gal-1-P values Ͼ25% (possible GALE deficiency). The cases are grouped by the race of the NB to highlight the observation that the presence of a Duarte mutation in 6 cases was exclusively associated with Caucasian NBs, all with GALT values below the reference interval. For the African American NBs, GALE deficiency was diagnosed in 5 cases. In 2 cases, no remarkable abnormality was noted in the NB period, and in 7 cases (all non- Two hundred nine cases with Gal concentrations Ն1.110 mmol/L (Ն20 mg/dL) and/or GALT values Յ40 mol/L, 23 of which were reported as GALT-deficient galactosemia. Of the remaining 186 cases, 176 had typical Gal-1-P values, suggesting possible GALE deficiency, and 10 had low Gal-1-P values, suggesting possible GALK deficiency. WRI, within reference interval.
Caucasian), no further follow-up was recorded. Except for the 6 cases with the Duarte mutation, all NBs with Gal concentrations Ն1.665 mmol/L (Ն30 mg/dL) and GALT values Ͼ40 mol/L were non-Caucasian. The analysis of the data in Tables 1 and 2 led to recommendations (see Discussion) for a revised Gal cutoff of 1.665 mmol/L (30 mg/dL) for reporting non-GALT-deficient positives and for revised follow-up protocols for positive and inconclusive screening results (Fig. 2) . In the revised protocol, positive screens would require urgent notification and referral to the treatment center, with full dietary restrictions and evaluation/confirmatory testing. Inconclusive screens would not require urgent notification or dietary restrictions until after rescreening, and referral would occur only if the rescreening results were abnormal. The new cutoff and revised protocols were then implemented. Table 3 
Discussion
The screening data for galactosemia presented in Fig. 1 observations: We found no GALT-deficient galactosemia when the GALT value was Ͼ38 mol/L. On the basis of either DNA or clinical confirmation, we found 19 cases of GALT-deficient galactosemia, a frequency of approximately 1 in 68 400. The sensitivity for detecting GALT deficiency was 100% with the GALT cutoff of Յ40 mol/L; the positive predictive value with this cutoff was 83% (19 of 23 cases). No GALT-deficient cases were missed. Three cases reported as positive with GALT values Յ40 mol/L were heterozygous D/G. The vast majority of NBs who are D/G heterozygotes have GALT values in the interval of 41-150 mol/L (data not shown) and typically show improvement in GALT activity in the weeks after initial screening, as with the NB in case no. 9 in Table 1 . GALT DNA analysis is ancillary to screening and potentially a diagnostic aid. When mutations are found, such analysis is most useful for differentiating clinically true GALT deficiency from D/G galactosemia for the purpose of treatment. Treatment of D/G galactosemia is controversial; however, Ficicioglu et al. recently reported that long-term clinical and developmental outcomes in children with D/G galactosemia are good, regardless of any diet changes in the first year of life, and that there was no relationship between clinical/developmental outcomes and the concentrations of erythrocyte Gal-1-P and urine galactitol (8 ) . The GALT cutoff of 40 mol/L is sufficiently low to exclude most compound heterozygote D/G cases without missing true GALT-deficient galactosemias.
Of the 19 confirmed GALT-deficient galactosemias, we identified 2 GALT mutations in 14 cases (11 homozygotes, 3 compound heterozygotes), and 1 mutation in 4 cases. In 1 case, none of the mutations we tested for were present. With the 4 mutations tested, we expect to confirm 70%-80% of the mutations responsible for GALT deficiency with DNA analysis.
The vast majority (87%) of screen positives for galactosemia in the 5-year study were not GALT deficient. GALT-deficient galactosemias are expected to represent 95% of all true clinically important cases; that is, the frequencies of GALK deficiencies and clinically important GALE deficiencies are small by comparison. Therefore, few of these 186 cases are likely to represent clinically important cases of either of these deficiencies. By determining the Gal-1-P percentage in samples with Gal concentrations Ն1.100 mmol/L (Ն20 mg/dL), we were able to segregate these 186 cases into those with possible GALK deficiency (Gal-1-P Ͻ25%) and those with a possible GALE deficiency (Gal-1-P Ն25%). We identified 10 cases of possible GALK deficiencies, of which only 1 case [GALT, 299 mol/L; total Gal, 3.996 mmol/L (72 mg/dL)] was a confirmed positive. Early differentiation of possible GALK-deficient NBs from possible GALE-deficient NBs with the Gal-1-P percentage is an important additional step in guiding clinical decision-making in these cases.
The remaining 176 cases had results consistent with GALE deficiency. To investigate the possible GALE deficiencies, we carried out a follow-up of the subset of the 176 cases that had total Gal values Ն1665 mmol/L (Ն30 mg/dL) (n ϭ 20; see Table 2 ). The cases are grouped by race to highlight that all of the cases with a Duarte mutation were Caucasian NBs and that all of the remaining cases were non-Caucasian NBs. As expected, NBs who are Duarte heterozygotes or compound heterozygotes often have GALT activities less than the lower limit of 2 SDs (150 mol/L). All of the confirmed GALE deficiencies (including 1 profound deficiency) were African American NBs. Benign GALE deficiency has been reported to occur with a frequency of approximately 1 in 6200 African Americans and 1 in 64 000 Caucasians (9 ) . On the basis of these numbers, benign GALE deficiency should occur with a frequency comparable to that of classic galactosemia in our population mix. Our identification of only 6 cases may be partially attributed to an inability to obtain final diagnoses for some of the NBs listed in Table 2 . This result also suggests that some NBs with benign GALE deficiencies have Gal values Ͻ1.665 mmol/L (Ͻ30 mg/dL).
In March 2006, the second phase of the study was formulated. We presented our data in a conference call with representatives from the laboratory, the PA DOH Newborn Screening Program, and galactosemia treatment centers. We reviewed the numbers of cases and their apparent clinical classifications and requested input from the treatment center directors in assessing the appropriateness of the classifications, in defining the degree of urgency of notification and treatment for each category from their perspective, and in providing us with input on the treatment protocols.
The clinical input regarding urgency of reporting and treatment was central to our final recommendations. The focus of the discussion was primarily on the 156 cases among the group with possible GALE deficiency that had been called as positive and referred to galactosemia treatment centers. The treatment center directors commented that in their experience true GALK and GALE deficiencies are associated with very high Gal values, usually Ͼ3.330 mmol/L (Ͼ60 mg/dL). They proposed that a screening cutoff of 1.665 mmol/L (30 mg/dL) was a reasonably conservative value for detecting clinically important GALE or GALK deficiency. They further proposed that all NBs with Gal values Ͻ1.665 mmol/L (Ͻ30 mg/dL) and GALT values Ͼ40 mol/L be considered as nonurgent cases from a notification/treatment perspective. A repeat collection would be sufficient follow-up in these cases, with a persistent abnormal Gal result in the second sample being the signal for referral to a treatment center. One caveat was that any NB with a Gal value Ն0.8325 mmol/L (Ն15 mg/dL) who had been on Gal-free formula before sample collection would be automatically referred to a treatment center. With 1.665 mmol/L (30 mg/dL) as a Gal cutoff, 165 NBs in our first-phase study (156 possible GALE cases plus 9 possible GALK-deficiency cases) with Gal values Ͻ1.665 mmol/L (Ͻ30 mg/dL) could have been reported as inconclusive (unless the NB was on a Galfree diet before collection). Urgent calls with urgent referral to a galactosemia treatment center could have been avoided in these cases.
We developed a flow diagram that reflects the suggested changes (Fig. 2) . This flow diagram consolidates all samples with GALT values Յ40 mol/L and Gal values Ն1.665 mmol/L (Ն30 mg/dL) under positive reporting and consolidates all samples with GALT values Ͼ40 mol/L and Gal values Ն0.8325 mmol/L (Ն15 mg/dL) but Ͻ1.665 mmol/L (Ͻ30 mg/dL) as inconclusive. These suggested changes in definitions for positive and inconclusive classification were matched with the proposed revisions in clinical protocols for each classification: A positive screening result would be defined as a GALT-deficient galactosemia or as a Gal value Ն1.665 mmol/L (Ն30 mg/dL) and would require urgent notification, referral to a treatment center, full dietary restriction, and appropriate confirmatory testing. An inconclusive screening result would be defined as an initial GALT value Ͼ40 mol/L and a Gal concentration Ն832.5 mmol/L (15 mg/dL) but Ͻ1.665 mmol/L (30 mg/dL) and would not require urgent notification or dietary restriction, but it would require a repeat collection. Referral would then occur only if the NB was on a Gal-free diet before the first collection or if the result of the repeat screen was abnormal. Also included in Fig. 2 is the decision point for the NBscreening counselors to contact the primary care provider in the inconclusive arm to determine if the NB had been on a Gal-free diet before collection of the blood spot. If so, the NB would then be referred immediately to a treatment center. 3 were GALT-deficient galactosemias, 2 were GALE deficiencies, 1 was a D/G compound heterozygote variant, and 1 was lost to followup. For 2008, one of the 2 reported positives was GALT deficient. The other was identified as having 1 copy of a GALT mutation, but this NB was lost to follow-up. An audit of positive urgent calls in 2005 showed that of the 30 reported positives, 5 were true positives (2 GALT cases, 2 GALE cases, and 1 GALK-deficiency case), 7 cases were D/G galactosemia, 12 were ultimately diagnosed as galactosemia negative, 4 were carriers, and 2 were lost to follow-up. Clearly, unnecessary urgent calls on NBs with increased Gal values were eliminated by the protocol change. 2008 . This reduction was due to normalization of Gal results in repeat testing of the reclassified cases. The reduction in referrals represents a substantial savings in terms of the emotional stress on parents, the NB being spared from unnecessary referral, and the costs to the healthcare system.
Conclusion
The primary goal of NB screening for galactosemia is to identify GALT-deficient galactosemia. Semiquantitative GALT analysis with an appropriate cutoff identifies these cases with few false positives. When NB screening includes Gal quantification, the vast majority of reported galactosemias in NBs are nonclassic, however, and these NBs rarely require urgent treatment. The traditional Gal cutoff for galactosemia [1. 110 mmol/L (20 mg/dL)] is not optimal for urgent follow-up if the GALT value is Ͼ40 mol/L and leads to unnecessary urgent notification and initiation of treatment protocols, which can be avoided with selective monitoring of second samples. By combining the accumulated data for comprehensive galactosemia testing with the clini-cal expertise of metabolic specialists in the treatment centers, the PA DOH Newborn Screening Program was able to review and improve follow-up protocols for nonclassic galactosemia, thereby saving money, time, and stress on an already overburdened system.
